ArticleFrontiers in immunology2021
A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Stringent selection drives convergence toward omicron-like SARS-CoV-2 receptor-binding motifs.Nature communications · 2026Article
- Development of a Thermostable and Broadly Neutralizing Pan-Sarbecovirus Vaccine Candidate.ACS infectious diseases · 2026Article
- A Brief History of the Pichia pastoris Expression System.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Article
- Next-Generation Vaccines for Co-Circulating PEDV and TGEV: Integrating Nucleic Acid Platforms, Mucosal Delivery, and AI-Driven Antigen Design.Transboundary and emerging diseases · 2025Review
- Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens.NPJ vaccines · 2024Article
- Enhancing Immunogenicity of a Thermostable, Efficacious SARS-CoV-2 Vaccine Formulation through Oligomerization and Adjuvant Choice.Pharmaceutics · 2023Article
- Mutations in S2 subunit of SARS-CoV-2 Omicron spike strongly influence its conformation, fusogenicity, and neutralization sensitivity.Journal of virology · 2023Article
- Enhanced protective efficacy of a thermostable RBD-S2 vaccine formulation against SARS-CoV-2 and its variants.NPJ vaccines · 2023Article
- UVC-Based Air Disinfection Systems for Rapid Inactivation of SARS-CoV-2 Present in the Air.Pathogens (Basel, Switzerland) · 2023Article
- Article
- Neutralizing Efficacy of Encapsulin Nanoparticles against SARS-CoV2 Variants of Concern.Viruses · 2023Article
- Mechanistic insights into global suppressors of protein folding defects.PLoS genetics · 2022Article
- Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting.International journal of molecular sciences · 2022Review
- Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice.Viruses · 2022Article
- Identification of stabilizing point mutations through mutagenesis of destabilized protein libraries.The Journal of biological chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 7 institutions in 3 countries.
Shahbaz AhmedMolecular Biophysics Unit (MBU), Indian Institute of Science, Bengaluru, India.
Mohammad Suhail KhanMolecular Biophysics Unit (MBU), Indian Institute of Science, Bengaluru, India.
Savitha GayathriMolecular Biophysics Unit (MBU), Indian Institute of Science, Bengaluru, India.
Randhir SinghMynvax Private Limited, ES12, Entrepreneurship Centre, Society for Innovation and Development (SID), Indian Institute of Science, Bengaluru, India.
Sahil KumarVirology Unit, Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Chandigarh, India.
Unnatiben Rajeshbhai PatelMynvax Private Limited, ES12, Entrepreneurship Centre, Society for Innovation and Development (SID), Indian Institute of Science, Bengaluru, India.
Sameer Kumar MalladiMolecular Biophysics Unit (MBU), Indian Institute of Science, Bengaluru, India.
Raju S RajmaniMolecular Biophysics Unit (MBU), Indian Institute of Science, Bengaluru, India.
Petrus Jansen van VurenAustralian Centre for Disease Preparedness (ACDP), Commonwealth Scientific and Industrial Research Organisation (CSIRO), Geelong, VIC, Australia.
Shane RiddellAustralian Centre for Disease Preparedness (ACDP), Commonwealth Scientific and Industrial Research Organisation (CSIRO), Geelong, VIC, Australia.
Sarah GoldieAustralian Centre for Disease Preparedness (ACDP), Commonwealth Scientific and Industrial Research Organisation (CSIRO), Geelong, VIC, Australia.
Nidhi GirishMynvax Private Limited, ES12, Entrepreneurship Centre, Society for Innovation and Development (SID), Indian Institute of Science, Bengaluru, India.
Poorvi ReddyMynvax Private Limited, ES12, Entrepreneurship Centre, Society for Innovation and Development (SID), Indian Institute of Science, Bengaluru, India.
Aditya UpadhyayaMynvax Private Limited, ES12, Entrepreneurship Centre, Society for Innovation and Development (SID), Indian Institute of Science, Bengaluru, India.
Suman PandeyMynvax Private Limited, ES12, Entrepreneurship Centre, Society for Innovation and Development (SID), Indian Institute of Science, Bengaluru, India.
Samreen SiddiquiMax Super Speciality Hospital (A Unit of Devki Devi Foundation), Max Healthcare, Delhi, India.
Akansha TyagiMax Super Speciality Hospital (A Unit of Devki Devi Foundation), Max Healthcare, Delhi, India.
Sujeet JhaMax Super Speciality Hospital (A Unit of Devki Devi Foundation), Max Healthcare, Delhi, India.
Rajesh PandeyINtegrative GENomics of HOst-PathogEn (INGEN-HOPE) Laboratory, Council of Scientific and Industrial Research (CSIR)-Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi, India.
Oyahida KhatunDepartment of Microbiology & Cell Biology, Indian Institute of Science, Bengaluru, India.
Rohan NarayanDepartment of Microbiology & Cell Biology, Indian Institute of Science, Bengaluru, India.
Shashank TripathiDepartment of Microbiology & Cell Biology, Indian Institute of Science, Bengaluru, India.
Alexander J McAuleyAustralian Centre for Disease Preparedness (ACDP), Commonwealth Scientific and Industrial Research Organisation (CSIRO), Geelong, VIC, Australia.
Nagendrakumar Balasubramanian SinganallurAustralian Centre for Disease Preparedness (ACDP), Commonwealth Scientific and Industrial Research Organisation (CSIRO), Geelong, VIC, Australia.
Seshadri S VasanAustralian Centre for Disease Preparedness (ACDP), Commonwealth Scientific and Industrial Research Organisation (CSIRO), Geelong, VIC, Australia.
Rajesh P RingeVirology Unit, Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Chandigarh, India.
Raghavan VaradarajanMolecular Biophysics Unit (MBU), Indian Institute of Science, Bengaluru, India.
Indian Institute of Science Bangalore · INCommonwealth Scientific and Industrial Research Organisation · AUAustralian Centre for Disease Preparedness · AUCouncil of Scientific and Industrial Research · INMax Healthcare · INInstitute of Microbial Technology · INMax Super Speciality Hospital · IN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Saturation suppressor mutagenesis was used to generate thermostable mutants of the SARS-CoV-2 spike receptor-binding domain (RBD). A triple mutant with an increase in thermal melting temperature of ~7°C with respect to the wild-type B.1 RBD and was expressed in high yield in both mammalian cells and the microbial host,
Indexed as
AnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesCricetinaeImmunogenicity, VaccineMiceSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2hamster immunizationhyperstable mutantslyophilizationneutralizing antibodiesstabilizing mutationthermotolerancevaccination
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.